| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5707 | 2021 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1769 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1425 | 2021 |
| Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs CCD Joe, J Jiang, T Linke, Y Li, S Fedosyuk, G Gupta, A Berg, ... Biotechnology and bioengineering 119 (1), 48-58, 2022 | 56 | 2022 |
| Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components S Fedosyuk, T Merritt, MP Peralta-Alvarez, SJ Morris, A Lam, N Laroudie, ... Vaccine 37 (47), 6951-6961, 2019 | 41 | 2019 |
| Characterization and structure of the vaccinia virus NF-κB antagonist A46 S Fedosyuk, I Grishkovskaya, E de Almeida Ribeiro, T Skern Journal of Biological Chemistry 289 (6), 3749-3762, 2014 | 38 | 2014 |
| Structure of human dipeptidyl peptidase 10 (DPPY): a modulator of neuronal Kv4 channels GA Bezerra, E Dobrovetsky, A Seitova, S Fedosyuk, S Dhe-Paganon, ... Scientific reports 5 (1), 8769, 2015 | 36 | 2015 |
| Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies WM Ng, S Fedosyuk, S English, G Augusto, A Berg, L Thorley, ... Cell host & microbe 30 (9), 1219-1230. e7, 2022 | 30 | 2022 |
| Vaccinia virus immunomodulator A46: A lipid and protein-binding scaffold for sequestering host TIR-domain proteins S Fedosyuk, GA Bezerra, K Radakovics, TK Smith, M Sammito, N Bobik, ... PLoS Pathogens 12 (12), e1006079, 2016 | 23 | 2016 |
| Bacterial protease uses distinct thermodynamic signatures for substrate recognition GA Bezerra, Y Ohara-Nemoto, I Cornaciu, S Fedosyuk, G Hoffmann, ... Scientific Reports 7 (1), 2848, 2017 | 19 | 2017 |
| Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial D Jenkin, AJ Ritchie, J Aboagye, S Fedosyuk, L Thorley, ... The Lancet Microbe 3 (9), e663-e671, 2022 | 18 | 2022 |
| Stability of chimpanzee adenovirus vectored vaccines (ChAdOx1 and ChAdOx2) in liquid and lyophilised formulations A Berg, D Wright, P Dulal, A Stedman, S Fedosyuk, MJ Francis, ... Vaccines 9 (11), 1249, 2021 | 18 | 2021 |
| Monolithic anion-exchange chromatography yields rhinovirus of high purity G Allmaier, D Blaas, C Bliem, T Dechat, S Fedosyuk, I Gösler, H Kowalski, ... Journal of virological methods 251, 15-21, 2018 | 15 | 2018 |
| Vaccinia virus immunomodulator A46: destructive interactions with MAL and MyD88 shown by negative-stain electron microscopy DF Azar, M Haas, S Fedosyuk, MH Rahaman, A Hedger, B Kobe, T Skern Structure 28 (12), 1271-1287. e5, 2020 | 12 | 2020 |
| NMR analysis of the interaction of picornaviral proteinases Lb and 2A with their substrate eukaryotic initiation factor 4GII M Aumayr, S Fedosyuk, K Ruzicska, C Sousa‐Blin, G Kontaxis, T Skern Protein Science 24 (12), 1979-1996, 2015 | 11 | 2015 |
| In vitro RNA release from a human rhinovirus monitored by means of a molecular beacon and chip electrophoresis VU Weiss, C Bliem, I Gösler, S Fedosyuk, M Kratzmeier, D Blaas, ... Analytical and Bioanalytical Chemistry 408, 4209-4217, 2016 | 3 | 2016 |
| Full wwPDB X-ray Structure Validation Report i Y Wang Word wide protein data bank, 2009 | 2 | 2009 |
| Stabilised viral fusion proteins A Douglas, S Fedosyuk US Patent App. 17/910,598, 2023 | 1 | 2023 |
| Rapid, cost-effective and scalable gmp-compliant simian adenovirus-vectored vaccine production for early-phase clinical trials using entirely disposable product-contact components A Douglas, T Merritt, S Fedosyuk, A Ritchie, P Angell-Manning, S Gilbert, ... | | 2018 |
| In vitro RNA release from a human rhinovirus monitored by means of a molecular beacon and chip electrophoresis (vol 408, pg 4209, 2016) VU Weiss, C Bliem, I Goesler, S Fedosyuk, M Kratzmeier, D Blaas, ... ANALYTICAL AND BIOANALYTICAL CHEMISTRY 408 (16), 4465-4465, 2016 | | 2016 |
